Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 42

1.

Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes.

Holman RR, Bethel MA, Mentz RJ, Thompson VP, Lokhnygina Y, Buse JB, Chan JC, Choi J, Gustavson SM, Iqbal N, Maggioni AP, Marso SP, Öhman P, Pagidipati NJ, Poulter N, Ramachandran A, Zinman B, Hernandez AF; EXSCEL Study Group.

N Engl J Med. 2017 Sep 28;377(13):1228-1239. doi: 10.1056/NEJMoa1612917. Epub 2017 Sep 14.

2.

Liraglutide and Renal Outcomes in Type 2 Diabetes.

Mann JFE, Ørsted DD, Brown-Frandsen K, Marso SP, Poulter NR, Rasmussen S, Tornøe K, Zinman B, Buse JB; LEADER Steering Committee and Investigators.

N Engl J Med. 2017 Aug 31;377(9):839-848. doi: 10.1056/NEJMoa1616011.

3.

Efficacy and Safety of Degludec versus Glargine in Type 2 Diabetes.

Marso SP, McGuire DK, Zinman B, Poulter NR, Emerson SS, Pieber TR, Pratley RE, Haahr PM, Lange M, Brown-Frandsen K, Moses A, Skibsted S, Kvist K, Buse JB; DEVOTE Study Group.

N Engl J Med. 2017 Aug 24;377(8):723-732. doi: 10.1056/NEJMoa1615692. Epub 2017 Jun 12.

4.

Predictors of Cognitive Decline in Older Adult Type 2 Diabetes from the Veterans Affairs Diabetes Trial.

Zimering MB, Knight J, Ge L, Bahn G; VADT Investigators.

Front Endocrinol (Lausanne). 2016 Sep 8;7:123. doi: 10.3389/fendo.2016.00123. eCollection 2016.

5.

Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes.

Marso SP, Daniels GH, Brown-Frandsen K, Kristensen P, Mann JF, Nauck MA, Nissen SE, Pocock S, Poulter NR, Ravn LS, Steinberg WM, Stockner M, Zinman B, Bergenstal RM, Buse JB; LEADER Steering Committee; LEADER Trial Investigators.

N Engl J Med. 2016 Jul 28;375(4):311-22. doi: 10.1056/NEJMoa1603827. Epub 2016 Jun 13.

6.

Follow-up of glycemic control and cardiovascular outcomes in type 2 diabetes.

Hayward RA, Reaven PD, Wiitala WL, Bahn GD, Reda DJ, Ge L, McCarren M, Duckworth WC, Emanuele NV; VADT Investigators.

N Engl J Med. 2015 Jun 4;372(23):2197-206. doi: 10.1056/NEJMoa1414266. Erratum in: N Engl J Med. 2015 Jul 9;373(2):198.

7.

The development and utility of a novel scale that quantifies the glycemic progression toward type 1 diabetes over 6 months.

Sosenko JM, Skyler JS, Beam CA, Boulware D, Mahon JL, Krischer JP, Greenbaum CJ, Rafkin LE, Matheson D, Herold KC, Palmer JP; Type 1 Diabetes TrialNet and Diabetes Prevention Trial–Type 1 Study Groups.

Diabetes Care. 2015 May;38(5):940-2. doi: 10.2337/dc14-2787. Epub 2015 Mar 10.

8.

Acceleration of the loss of the first-phase insulin response during the progression to type 1 diabetes in diabetes prevention trial-type 1 participants.

Sosenko JM, Skyler JS, Beam CA, Krischer JP, Greenbaum CJ, Mahon J, Rafkin LE, Matheson D, Herold KC, Palmer JP; Type 1 Diabetes TrialNet and Diabetes Prevention Trial–Type 1 Study Groups.

Diabetes. 2013 Dec;62(12):4179-83. doi: 10.2337/db13-0656. Epub 2013 Jul 17.

9.

The prediction of type 1 diabetes by multiple autoantibody levels and their incorporation into an autoantibody risk score in relatives of type 1 diabetic patients.

Sosenko JM, Skyler JS, Palmer JP, Krischer JP, Yu L, Mahon J, Beam CA, Boulware DC, Rafkin L, Schatz D, Eisenbarth G; Type 1 Diabetes TrialNet Study Group; Diabetes Prevention Trial-Type 1 Study Group.

Diabetes Care. 2013 Sep;36(9):2615-20. doi: 10.2337/dc13-0425. Epub 2013 Jul 1.

10.

Insulin degludec improves glycaemic control with lower nocturnal hypoglycaemia risk than insulin glargine in basal-bolus treatment with mealtime insulin aspart in Type 1 diabetes (BEGIN(®) Basal-Bolus Type 1): 2-year results of a randomized clinical trial.

Bode BW, Buse JB, Fisher M, Garg SK, Marre M, Merker L, Renard E, Russell-Jones DL, Hansen CT, Rana A, Heller SR; BEGIN® Basal-Bolus Type 1 trial investigators.

Diabet Med. 2013 Nov;30(11):1293-7. doi: 10.1111/dme.12243. Epub 2013 Jun 17.

11.

Risk of adrenal crisis in dental patients: results of a systematic search of the literature.

Khalaf MW, Khader R, Cobetto G, Yepes JF, Karounos DG, Miller CS.

J Am Dent Assoc. 2013 Feb;144(2):152-60. Review.

PMID:
23372131
12.

Pathophysiology and management strategies for hyperglycemia for patients with acute illness during and following a hospital stay.

Dombrowski NC, Karounos DG.

Metabolism. 2013 Mar;62(3):326-36. doi: 10.1016/j.metabol.2012.07.020. Epub 2012 Sep 20. Review.

PMID:
22999713
13.

Extended longitudinal analysis of arterial pressure and heart rate control in unanesthetized rats with type 1 diabetes.

Anigbogu CN, Speakman RO, Silcox DL, Brown LV, Brown DR, Gong MC, Patwardhan AR, Reynolds LR, Karounos DG, Burgess DE, Baldridge BR, Randall DC.

Auton Neurosci. 2012 Sep 25;170(1-2):20-9. doi: 10.1016/j.autneu.2012.06.006. Epub 2012 Jul 17.

14.

Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 1 diabetes (BEGIN Basal-Bolus Type 1): a phase 3, randomised, open-label, treat-to-target non-inferiority trial.

Heller S, Buse J, Fisher M, Garg S, Marre M, Merker L, Renard E, Russell-Jones D, Philotheou A, Francisco AM, Pei H, Bode B; BEGIN Basal-Bolus Type 1 Trial Investigators.

Lancet. 2012 Apr 21;379(9825):1489-97. doi: 10.1016/S0140-6736(12)60204-9.

PMID:
22521071
15.

The duration of diabetes affects the response to intensive glucose control in type 2 subjects: the VA Diabetes Trial.

Duckworth WC, Abraira C, Moritz TE, Davis SN, Emanuele N, Goldman S, Hayward R, Huang GD, Marks JB, Reaven PD, Reda DJ, Warren SR, Zieve FJ; Investigators of the VADT.

J Diabetes Complications. 2011 Nov-Dec;25(6):355-61. doi: 10.1016/j.jdiacomp.2011.10.003. Epub 2011 Nov 4.

PMID:
22055259
16.

Blood pressure regulation in diabetic patients with and without peripheral neuropathy.

Wang S, Randall DC, Knapp CF, Patwardhan AR, Nelson KR, Karounos DG, Evans JM.

Am J Physiol Regul Integr Comp Physiol. 2012 Mar 1;302(5):R541-50. doi: 10.1152/ajpregu.00174.2011. Epub 2011 Nov 2.

17.

Longitudinal analysis of arterial blood pressure and heart rate response to acute behavioral stress in rats with type 1 diabetes mellitus and in age-matched controls.

Randall DC, Speakman RO, Silcox DL, Brown LV, Brown DR, Gong MC, Patwardhan A, Reynolds LR, Karounos DG, Burgess DE, Anigbogu CN.

Front Physiol. 2011 Aug 27;2:53. doi: 10.3389/fphys.2011.00053. eCollection 2011.

18.

Circadian Variations in Blood Pressure, Heart Rate, and HR-BP Cross-Correlation Coefficient during Progression of Diabetes Mellitus in Rat.

Anigbogu CN, Williams DT, Brown DR, Silcox DL, Speakman RO, Brown LC, Karounos DG, Randall DC.

Int J Hypertens. 2011;2011:738689. doi: 10.4061/2011/738689. Epub 2011 Apr 19.

19.

Intensive insulin protocol implementation and outcomes in the medical and surgical wards at a Veterans Affairs Medical Center.

Chen HJ, Steinke DT, Karounos DG, Lane MT, Matson AW.

Ann Pharmacother. 2010 Feb;44(2):249-56. doi: 10.1345/aph.1M501. Epub 2010 Jan 26.

PMID:
20103610
20.

Glucose control and vascular complications in veterans with type 2 diabetes.

Duckworth W, Abraira C, Moritz T, Reda D, Emanuele N, Reaven PD, Zieve FJ, Marks J, Davis SN, Hayward R, Warren SR, Goldman S, McCarren M, Vitek ME, Henderson WG, Huang GD; VADT Investigators.

N Engl J Med. 2009 Jan 8;360(2):129-39. doi: 10.1056/NEJMoa0808431. Epub 2008 Dec 17. Erratum in: N Engl J Med. 2009 Sep 3;361(10):1028. N Engl J Med. 2009 Sep 3;361(10):1024-5.

Supplemental Content

Loading ...
Support Center